Fatty acid amide hydrolase 2 (FAAH2)

Fatty acid amide hydrolase 2 is a membrane-associated enzyme that catalyzes the hydrolysis of various bioactive lipids from the main classes of fatty acid amides, including N-acylethanolamines, fatty acid primary amides, and N-acyl amino acids. It shows preference for monounsaturated acyl chains as substrates, and its activity regulates the levels and signaling of molecules such as anandamide and oleamide. FAAH2 is expressed in humans and has structural similarity to the more widely studied FAAH enzyme. Diseases associated with mutations or dysfunction of FAAH2 include intellectual disability syndromes and autism spectrum disorder. FAAH2 has not been as extensively studied as FAAH, and there are currently fewer drugs directly targeting FAAH2, though the modulation of related lipid signaling pathways is of pharmacological interest. Its molecular classification is as an amidase signature enzyme, and it is implicated in the regulation of endocannabinoid signaling and metabolic homeostasis. If more detailed drug-target interaction data or recent biomarker findings are required for FAAH2 specifically, further targeted database searches or literature reviews would be recommended, as current knowledge is primarily based on the related FAAH enzyme.

Other names

Fatty acid amide hydrolase 2FAAH2FAAH-2fatty-acid amide hydrolase 2

Inhibitors would block the hydrolysis of fatty acid amides, increasing their signaling function within the endocannabinoid system.